{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-003565","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2023-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.987893+00:00","generated_at":"2026-06-19T11:04:47.560073+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Ardelyx amends SLR loan; extends interest-only and draw deadlines conditional on FDA tenapanor decision","bullets":["Interest-only period extended to April 1, 2025 if FDA approves tenapanor hyperphosphatemia NDA by Nov 30, 2023 or 2023 revenue milestones met.","Draw period for additional $22.5M Term B Loan extended to Dec 20, 2023, tied to same FDA approval timeline.","Interest rate revised to 7.95% + greater of 1% or (0.022% + 1-month CME Term SOFR).","Amendment provides financial flexibility while awaiting FDA decision on tenapanor."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-003565","json":"https://secwatch.observer/filing/0001628280-23-003565.json","markdown":"https://secwatch.observer/filing/0001628280-23-003565.md","text":"https://secwatch.observer/filing/0001628280-23-003565.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023003565/0001628280-23-003565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023003565/ardx-20230209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T11:04:47.560073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d250d09a9cb82a0f07883588cd1bebdf541c34a","claim":"ARDELYX, INC. amended credit facility with SLR Investment Corp., as collateral agent, and the lenders listed on Schedule 1.1 to the Loan Agreement at 7.95% plus the greater of (a) one percent (1.00%) per annum and (b)(i) 0.022% pl.","evidence_excerpt":"On February 9, 2023, we entered into a second amendment (the “Second Amendment”) to our loan and security agreement (the “Loan Agreement”) with SLR Investment Corp., as collateral agent (the “Agent”), and the lenders listed on Schedule 1.1 to the Loan Agreement (collectively the “Lenders”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023003565/0001628280-23-003565-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Counterparty","value":"SLR Investment Corp., as collateral agent, and the lenders listed on Schedule 1.1 to the Loan Agreement"},{"label":"Rate","value":"7.95% plus the greater of (a) one percent (1.00%) per annum and (b)(i) 0.022% pl"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"a083e37efafa908f7d438c1fac88eb8f3fd030b6","claim":"ARDELYX, INC. amended Second Amendment with SLR Investment Corp., as collateral agent, and the lenders listed on Schedule 1.1 to the Loan Agreement (effective 2023-02-09).","evidence_excerpt":"On February 9, 2023, we entered into a second amendment (the “Second Amendment”) to our loan and security agreement (the “Loan Agreement”) with SLR Investment Corp., as collateral agent (the “Agent”), and the lenders listed on Schedule 1.1 to the Loan Agreement (collectively the “Lenders”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023003565/0001628280-23-003565-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"SLR Investment Corp., as collateral agent, and the lenders listed on Schedule 1.1 to the Loan Agreement"},{"label":"Effective","value":"2023-02-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}